PFE FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
PFE FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
Story updates
08:31:08 PM UTC
SquawkNews
PFE FDA grants priority review for pfizer’s talzenna plus xtandi for the treatment of metastatic prostate cancer Pfizer - FDA sets pdufa action date for talzenna plus xtandi in Q4 2026
08:35:59 PM UTC
SquawkNews
PFE - FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
08:39:47 PM UTC
SquawkNews
Pfizer announced that the...
PFE FDA grants priority review for pfizer’s talzenna plus xtandi for the treatment of metastatic prostate cancer Pfizer - FDA sets pdufa action date for talzenna plus xtandi in Q4 2026